Oncternal Therapeutics, Inc. (NASDAQ:ONCT) Short Interest Update

Oncternal Therapeutics, Inc. (NASDAQ:ONCT) was the recipient of a large drop in short interest in November. As of November 15th, there was short interest totalling 14,200 shares, a drop of 68.7% from the October 31st total of 45,400 shares. Approximately 0.5% of the shares of the stock are sold short. Based on an average daily trading volume, of 119,900 shares, the days-to-cover ratio is presently 0.1 days.

Wall Street Analyst Weigh In

ONCT has been the subject of a number of research reports. Brookline Capital Management reaffirmed a “hold” rating on shares of Oncternal Therapeutics in a report on Thursday, September 12th. Northland Capmk cut shares of Oncternal Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, September 12th. Northland Securities reissued a “market perform” rating and issued a $2.00 target price on shares of Oncternal Therapeutics in a research note on Thursday, September 12th. StockNews.com assumed coverage on Oncternal Therapeutics in a report on Wednesday. They set a “hold” rating on the stock. Finally, HC Wainwright cut their price target on Oncternal Therapeutics from $19.00 to $18.00 and set a “buy” rating for the company in a report on Monday, August 12th. Four analysts have rated the stock with a hold rating and one has given a buy rating to the company. Based on data from MarketBeat, Oncternal Therapeutics presently has an average rating of “Hold” and an average price target of $20.00.

Institutional Trading of Oncternal Therapeutics

A hedge fund recently bought a new stake in Oncternal Therapeutics stock. Pasadena Private Wealth LLC bought a new stake in Oncternal Therapeutics, Inc. (NASDAQ:ONCT) in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 25,000 shares of the company’s stock, valued at approximately $190,000. Pasadena Private Wealth LLC owned about 0.84% of Oncternal Therapeutics as of its most recent filing with the Securities & Exchange Commission. 16.05% of the stock is currently owned by hedge funds and other institutional investors.

Oncternal Therapeutics Stock Performance

Shares of ONCT remained flat at $0.75 during mid-day trading on Wednesday. The stock had a trading volume of 146,592 shares, compared to its average volume of 41,696. Oncternal Therapeutics has a fifty-two week low of $0.62 and a fifty-two week high of $13.14. The firm has a market capitalization of $2.21 million, a PE ratio of -0.06 and a beta of 1.33. The firm’s 50-day moving average price is $1.33 and its 200 day moving average price is $4.71.

About Oncternal Therapeutics

Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.